NCT02285205View on ClinicalTrials.gov

A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Type 2 DiabetesNon-alcoholic Fatty Liver Disease

Interventions

DRUG

Oral administration of Lobeglitazone

Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks

Trial Locations (1)

120-752

Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER

NCT02285205 - A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD | Biotech Hunter | Biotech Hunter